X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Clinical Trials Regulation Implementation Progress Report

    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    5 FDA Rulings To Keep An Eye On In The 2023 First Quarter

    Drugs To Watch For In 2023 That Could Become Blockbusters

    Gut Microbiota Is Important In Parkinsons, As Per A Study

    A Breakthrough Medication For Dystonia Is Being Developed

    Australia Introduces A New Tool To Lower Medicine Costs

    Dupixent Charts A Win Before The FDA Prurigo Nodularis Order

    Hong Kong University Creates Bone Anabolic Aptamer Drug

    Developing Drugs That Target Multidrug-Resistant Bacteria

    Persistent Bacteria Are Undermining Antibiotic Treatment

    First Treatment For Advanced ASPS Is Given The Green Light

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Clinical Trials Regulation Implementation Progress Report

    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    5 FDA Rulings To Keep An Eye On In The 2023 First Quarter

    Drugs To Watch For In 2023 That Could Become Blockbusters

    Gut Microbiota Is Important In Parkinsons, As Per A Study

    A Breakthrough Medication For Dystonia Is Being Developed

    Australia Introduces A New Tool To Lower Medicine Costs

    Dupixent Charts A Win Before The FDA Prurigo Nodularis Order

    Hong Kong University Creates Bone Anabolic Aptamer Drug

    Developing Drugs That Target Multidrug-Resistant Bacteria

    Persistent Bacteria Are Undermining Antibiotic Treatment

    First Treatment For Advanced ASPS Is Given The Green Light

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Facilities & Operation

Considerable Rise In Healthcare Deals Expected In 2023

Content Team by Content Team
16th January 2023
in Facilities & Operation, News

Pharma companies with plenty of cash were on one side of a $200 billion patent cliff. On the other hand, there were a lot of smaller biotech companies that were cash-strapped and offering assets at a discount. These companies’ valuations had suffered during the market slump.

However, 2022 ended up being a somewhat slow year. According to a report released by S&P Global Market Intelligence on December 19 last year, the total deal value in the health industry has decreased by 56% to $202 billion by December end.

The slowness was partly due to unbalanced expectations. Some target company chief executives were reluctant to accept a valuation reset immediately due to the stock market’s extreme volatility in 2022 following a phenomenal 2021. Acquirers, meanwhile, viewed the 2021 highs as ceilings rather than a realistic starting point for negotiations. Joseph Wolk, the chief financial officer of Johnson & Johnson, stated as much to analysts on earnings call in October when he claimed that sellers holding onto their record highs from 2021 didn’t promote deal-making.

Even so, the distance between acquirers and their targets is gradually beginning to close. Following Mr. Wolk’s remarks, J&J announced on Nov. 1 that it had reached an agreement to acquire heart pump manufacturer Abiomed for $16.6 billion in cash, making it one of the year’s biggest healthcare deals. Although it was close to the company’s 52-week high, achieved in November 2021, the $380 price per share represented nearly a 50% premium over Abiomed’s closing price the day before the announcement of the deal. The $28 billion purchase of Horizon Therapeutics by Amgen, which was disclosed earlier in December, was the largest healthcare transaction of the year. The $116.50 per share was about where Horizon was trading a year ago, while representing an almost 50% premium over the closing price before news of the talks.

The two significant transactions in the latter two months of 2022 indicate that the bid-to-ask spreads are beginning to close, which suggests that 2023 might be a much stronger year for M&A. As top-selling pharmaceuticals lose their patent exclusivity, many drug and medical device firms are just getting started, with plenty of balance-sheet capacity and hunger. In contrast, Amgen may be reaching its limit given how leveraged it gets after the Horizon transaction.

Despite the Abiomed transaction, J&J is anticipated to be one of the top acquirers in 2019. It was one of Horizon’s initial suitors, and it’s believed that it would keep looking for agreements until the patent on its best-selling immunology medication, Stelara, expires. Pfizer will probably be another significant dealmaker in 2023. Pfizer appears to be choosing to do a series of smaller purchases rather than a megadeal, despite the fact that it may have the most deal capability and the greatest need considering the risk to certain of its product lines. Pfizer acquired Arena for $6.7 billion, Global Blood Therapeutics for $5.4 billion, Biohaven for $11.6 billion, and ReViral for less than $1 billion in the year 2022 alone. According to Goldman Sachs, Pfizer has an extra $100 billion in firepower between its cash on hand and its capacity to take on debt.

Merck might announce a major agreement. Prior to reaching a snag, the company was in negotiations to acquire Seagen for around $40 billion. However, management has left the option of striking a sizable deal open as it seeks to offset the anticipated revenue loss when Keytruda, its popular cancer medication, loses its patent protection later this decade.

According to a forecast by PricewaterhouseCoopers, the total value of M&A transactions in the pharmaceutical and life sciences sector might reach $225 billion to $275 billion in 2023. With so much untapped potential and a wide range of prospects, deal-making this year is expected to pick up steam.

Previous Post

A New Advancement In Disease Fighting Through Technology

Related Posts

IPR Data Management

A New Advancement In Disease Fighting Through Technology

13th January 2023
Clinical Trials

Clinical Trials Regulation Implementation Progress Report

13th January 2023
IPR Data Management

5 Concerns About Future of Developing Biotechnology In 2023

13th January 2023
Usual Pharma Compliance Issues Noted In FDA Warning Letters
FDA Approvals

5 FDA Rulings To Keep An Eye On In The 2023 First Quarter

13th January 2023
Drug Development

Drugs To Watch For In 2023 That Could Become Blockbusters

13th January 2023
News

Gut Microbiota Is Important In Parkinsons, As Per A Study

12th January 2023

Latest News

Facilities & Operation

Considerable Rise In Healthcare Deals Expected In 2023

16th January 2023
IPR Data Management

A New Advancement In Disease Fighting Through Technology

13th January 2023
Clinical Trials

Clinical Trials Regulation Implementation Progress Report

13th January 2023
IPR Data Management

5 Concerns About Future of Developing Biotechnology In 2023

13th January 2023
Usual Pharma Compliance Issues Noted In FDA Warning Letters
FDA Approvals

5 FDA Rulings To Keep An Eye On In The 2023 First Quarter

13th January 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In